Drug Profile
Research programme: anticancer antibodies - Cellerant Therapeutics
Alternative Names: CSC 17.7; CSC17.1Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Cellerant Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer